I'm more curious on your take on the S.A. post. If you have yet to do so, I suggest you (and everyone else) read it; it's good stuff!
sno, everything is relative; what seems like a lot to some may seem like a little to others.
You don't help your "argument" when you employ "mine is bigger than yours"; by doing so, you simply confirm that you are a tool.
You are clearly underdiversified and are suffering as a result.
Hey Matt, I think you (and most everyone) would like to read a recent post on Seeking Alpha.
If the link below does not work, simply Google " Behind the scenes with dream team".
The post was written by a former banker who was approached to write "reaearch" articles to increase demand for a stock. Fallout from the company's action may mean they lose the proceeds from a recent equity offering. Lots of unscrupulous people who post!!!
I had the same reaction re the Super Bowl ad "joke". I plan to read the text of the call to review certain items, but when someone asked about "other marketing", I learned nothing new; I did hear "connecting with social media".
Great news! LWAY has 300K "followers" and 100K TWTR followers. Julie LOVES to tweet.
Bill, IMO sales of LWAY's products would be much more successful if the company were sold.
That said, I do not see the family selling out. The family has too good a thing going for them: high compensation, very nice benefits. The family are the reason this "growth" company pays a dividend instead of reinvesting the cash into the company (can you say advertising?).
Unrelated to the specific topic, but re K-1s, this is the first year I have received mulitiple K-1s re trusts that have foreign income. I've been using TurboTax for years, but am a tad disappointed that TT doesn't handle the multiple country identification very well at all. Then there's the state return with adjusted income amounts; again, TT not so straightfowrad, but with the use of the net, I've figured out what to do.
No, I would not recommend dumping ANY biotech fund "for some of the (presumably) stronger biotech stocks..."
While I own quite a few individual equities, I opted for the fund route for biotech exposure. The biotech sector is fraught with risk and IMO the best way to augment the risk is to be diversified. A fund offers decent diversification There are so many wild card situations; pickint the "right" stocks is too challenging for me and possibly for most retail investors.
That said, biotech represents a small piece of my holdings.
P.S. for those who want to trade the sector (and not be concerned about short term trading restrictions), I suggest trading an ETF.
"You are right this is not based on fundamental. It is based on fear or profit taking after 4 years of rally."
Dare I suggest some of the fantastic run-up was not based on fundamentals as well???
IMO, management did what was required to keep DMND running as an independent business. If the business succeeds, the share price will reflect this and shareholders will be rerwarded. There are risks involved when buying shares of a damaged company. Current management seems to be doing a good job.
“There is no other sector that can provide the enormous potential upside but also with the greatest amount of risk” (Peter Boockvar, The Lindsey Group)
"When there is great reward, investors don't mind the risk." (me_novice)
I am writing in generalities, my comments are not directed to any specific poster.
It seems that some have fairly large positions in biotech relative to their total holdings. Posters seemed to be fairly complacent until the recent modest sell-off. We are all aware of the "risk v reward" concept. Sure seemed like some posters DID mind the risk that was recently evident in this sector. I'm not saying biotech will crash, but I would not be surprised to see values lower in the future relative to other sectors. For those who have held biotech for a while, I think it might be prudent to take some profits. Nothing worse than seeing profits slowly erode while having the "commitment" to sell some shares "once the price moves back up to X". I know, from past experiences. There is something to be said about rebalancing a portfolio. If one initiated a position in this sector with X% weighting, most likely that weighting is now a tad high. By rebalancing, one sells high (maybe not the ultimate high, but high). I sold 20% of my biotech position in Jan; by doing so, I was not bothered in the least by the recent price movement. IF values increase even higher than the recent highs, I may sell some more; on the flipside, I have a lower target price to ADD, if that level is achieved.
I'm simply trying to add some perspective.
"Mr. Brian J. Driscoll has been the Chief Executive Officer and President at Diamond Foods, Inc. since May 8, 2012. Mr. Driscoll served as the Chief Executive Officer of Hostess Brands, Inc. from July 2010 to March 9, 2012 and also served as its President until March 09, 2012. Mr. Driscoll served as President of Sales Customer Service and Logistics at Kraft Foods Inc. He served as Senior Vice President of US Sales & Customer Service at Kraft Foods since March 14, 2003 ... and its Senior Vice President of Sales for North America Commercial. He has held senior roles at Nabisco, Nestlé USA and Procter & Gamble. He has been a Non Independent Director of Diamond Foods, Inc. since May 2012. Mr. Driscoll received a B.S. in Marketing and Finance from St. John's University."
"Mr. Raymond P. Silcock, also known as Ray, has been the Chief Financial Officer and Executive Vice President of Diamond Foods, Inc. since June 11, 2013. Mr. Silcock served as the Chief Financial Officer at The Great Atlantic & Pacific Tea Company, Inc. (A&P) since March 13, 2012. Mr. Silcock joined A&P in December 2011 as Head of Finance. Prior to joining A&P, he served as an Executive-in-Residence at Palm Ventures LLC. He served as the Chief Financial Officer and Executive ... Vice President of KB Home from September 2009 to December 14, 2009. Mr. Silcock served as the Chief Financial Officer and Senior Vice President of UST LLC, from August 6, 2007 to January 2009. Mr. Silcock served as an Executive Vice President of JBS USA Holdings, Inc. (formerly, Swift & Company) since November 6, 2006. He served as Chief Financial Officer of JBS USA Holdings, Inc. since November 6, 2006. He served as the Chief Financial Officer of Swift & Company from November 6, 2006 to 2007. Mr. Silcock provided consulting services to Blackstone and Morgan Stanley since 2005..."
There's more, but you probably won't grasp the facts.
"Usually a $5.00 price difference between WFC and USB and now almost a $7.00 per share difference."
Applying a basic math concept and given both USB and WFC share prices have increased, one would assume the share price differencial would increase. Of course, IMO, comparing two company's share prices in a vacuum is worthless. While I often see WFC mentioned on this board, I'm not really sure why. WFC's market cap, $259B, is larger than JPM's. USB has a market cap of $77B. Perhaps it is fair to describe USB as a baby WFC, hence the comparison.
While I had hoped for a larger div increase, I'll take the 6.5% increase.
Heck, over the past five years, USB has outperformed VTSAX, Vanguard's Total Market Index fund, my default benchmark--have other banks performed better? Sure, but I am content to continue to hold USB shares (and reinvest divs--Roth) along with shares in four other banks.
Maybe you need to SPAM the ELAY board (once again lol).
First you offed "aliostern" (sp?) and grabbed its turf (GRNH). Then you acquired two more accounts to SPAM:
ECOS and ELAY. But for some reason, you didn't SPAM the ELAY board this week. Why? Poor "work ethic"?
You sold all of you stocks or all of your CANN shares (or were you only long one stock?)